/KDNY

KDNY Stock - Chinook Therapeutics, Inc.

Q: What is the analyst price target for KDNY?

Analyst price target information is not currently available for KDNY.

Q: What is KDNY's market cap?

Market capitalization information is not currently available for KDNY.

Healthcare|Biotechnology|NASDAQ

$40.39+0.22%

+$0.09 (+0.22%) • Aug 10

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

100

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+-25.7%upside

Target: $30.01

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for KDNY

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2018

FY2019

FY2020

FY2021

FY2022

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.67

52W High$40.51

52W Low$18.34

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020	FY2019	FY2018
Revenue	$6.13M	$51.63M	$827,000	$17.26M	$15.09M
Gross Profit	$4.41M	$49.94M	$405,000	$16.70M	$14.50M
Gross Margin	71.9%	96.7%	49.0%	96.8%	96.1%
Operating Income	$-185,083,000	$-99,038,000	$-56,227,000	$-19,966,000	$-101,360,000
Net Income	$-184,615,000	$-101,301,000	$-81,622,000	$-46,851,000	$-95,357,000
Net Margin	-3012.6%	-196.2%	-9869.6%	-271.5%	-632.0%
EPS	$-2.87	$-2.22	$-6.20	$-1.11	$-0.00

Company Overview

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

67%

Hold / Neutral

33%

Sell / Underperform

Analyst Consensus🟡 Mixed

2 Bullish1 Neutral/Bearish

Price Targets

$37

Average Target

↓ 7.9% Downside

Now

$30

Low

$37

Average

$43

High

Based on 5 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
August 8th 2023	Wedbush	Downgrade	Neutral	$42
March 6th 2023	Piper Sandler	Initiation	Overweight	$41
March 1st 2023	Guggenheim	Initiation	Buy	$43
December 5th 2022	Wells Fargo	Initiation	Overweight	$30
June 28th 2022	Stifel	Initiation	Buy	$30

Earnings History & Surprises

KDNY

Beat Rate

40%

Last 15 quarters

Avg Surprise

-29.9%

EPS vs Estimate

Beats / Misses

6/9

Last 12 quarters

Latest EPS

$-0.94

Q3 2023

EPS Surprise History

Q4 21

+17.1%

$-0.68vs$-0.82

Q1 22

-79.4%

$0.14vs$0.68

Q2 22

+20.6%

$-0.54vs$-0.68

Q3 22

+1.6%

$-0.61vs$-0.62

Q4 22

-33.9%

$-0.83vs$-0.62

Q1 23

-13.9%

$-0.90vs$-0.79

Q2 23

-6.2%

$-0.85vs$-0.80

Q3 23

-16.0%

$-0.94vs$-0.81

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q3 2024	Aug 5, 2024	—	—	—	—
Q2 2024	May 7, 2024	—	—	—	—
Q1 2024	Feb 26, 2024	—	—	—	—
Q4 2023	Nov 9, 2023	$-0.84	—	—	—
Q3 2023	Aug 7, 2023	$-0.81	$-0.94	-16.0%	✗ MISS
Q2 2023	May 9, 2023	$-0.80	$-0.85	-6.2%	✗ MISS
Q1 2023	Feb 27, 2023	$-0.79	$-0.90	-13.9%	✗ MISS
Q4 2022	Nov 10, 2022	$-0.62	$-0.83	-33.9%	✗ MISS
Q3 2022	Aug 8, 2022	$-0.62	$-0.61	+1.6%	✓ BEAT
Q2 2022	May 12, 2022	$-0.68	$-0.54	+20.6%	✓ BEAT
Q1 2022	Mar 17, 2022	$0.68	$0.14	-79.4%	✗ MISS
Q4 2021	Nov 8, 2021	$-0.82	$-0.68	+17.1%	✓ BEAT
Q3 2021	Aug 12, 2021	$-0.76	$-0.68	+10.5%	✓ BEAT
Q2 2021	May 12, 2021	$-0.61	$-0.83	-36.1%	✗ MISS
Q4 2020	Dec 31, 2020	—	$-1.24	—	—
Q4 2020	Nov 5, 2020	$-0.23	$-0.90	-291.3%	✗ MISS
Q3 2020	Aug 3, 2020	$0.95	$1.05	+10.5%	✓ BEAT
Q2 2020	May 4, 2020	$0.67	$0.45	-32.8%	✗ MISS
Q1 2020	Mar 9, 2020	$1.05	$1.20	+14.3%	✓ BEAT
Q4 2019	Nov 7, 2019	$1.16	$1.00	-13.8%	✗ MISS

Frequently Asked Questions about KDNY

What is KDNY's current stock price?

Chinook Therapeutics, Inc. (KDNY) is currently trading at $40.39 per share. The stock has moved +0.22% today.

What is the analyst price target for KDNY?

The average analyst price target for KDNY is $30.00, based on 1 analyst.

What sector is Chinook Therapeutics, Inc. in?

Chinook Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is KDNY's market cap?

Chinook Therapeutics, Inc. has a market capitalization of $2.71 billion, making it a mid-cap company.

Does KDNY pay dividends?

No, Chinook Therapeutics, Inc. does not currently pay a dividend to shareholders.